Login / Signup

TGFβ-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression.

Shayin V GibsonElena Tomás-BortLucía Rodríguez-FernándezMichael D AllenJennifer J GommIain GouldingUlrich Auf dem KellerAndrea AgnolettoCathrin BriskenBarrie PeckAngus J CameronJohn F MarshallJ Louise JonesEdward Philip CarterRichard Philip Grose
Published in: NPJ breast cancer (2023)
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. Virtually all women with DCIS are treated, despite evidence suggesting up to half would remain with stable, non-threatening, disease. Overtreatment thus presents a pressing issue in DCIS management. To understand the role of the normally tumour suppressive myoepithelial cell in disease progression we present a 3D in vitro model incorporating both luminal and myoepithelial cells in physiomimetic conditions. We demonstrate that DCIS-associated myoepithelial cells promote striking myoepithelial-led invasion of luminal cells, mediated by the collagenase MMP13 through a non-canonical TGFβ - EP300 pathway. In vivo, MMP13 expression is associated with stromal invasion in a murine model of DCIS progression and is elevated in myoepithelial cells of clinical high-grade DCIS cases. Our data identify a key role for myoepithelial-derived MMP13 in facilitating DCIS progression and point the way towards a robust marker for risk stratification in DCIS patients.
Keyphrases